Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809149 | 0.88 | PTGER3 (0.33) | PTGER2RBP4KMT2ATSHRCYP2C9 | |
| SCHEMBL38997 | 0.83 | — | — | |
| SCHEMBL9739325 | 0.81 | PTGER3 (0.34) | PTGER2RBP4KMT2ATSHRCYP2C9 | |
| SCHEMBL27657095 | 0.80 | GAA (0.42) | PTGER2RBP4KMT2ATSHRPTGER4 | |
| SCHEMBL209037 | 0.80 | MAPT (0.37) | PTGER2KMT2ATSHRCYP2C9CYP2C19 | |
| SCHEMBL39320 | 0.79 | TBXAS1 (0.31) | — | |
| SCHEMBL6492997 | 0.78 | PTGFR (0.37) | FFAR4KMT2ATSHRPTGER3MAPT | |
| SCHEMBL9784227 | 0.77 | PTGFR (0.40) | PTGER2TSHRCYP2C9CYP2C19PTGER4 | |
| SCHEMBL39301 | 0.76 | — | — | |
| SCHEMBL1232053 | 0.76 | GAA (0.44) | KMT2ATSHRMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BASF SE (DE) | 2012-06-28 | — | — | US | claimed |
| US-8859235-B2 | Methods in cell cultures, and related inventions, employing certain additives | BASF SE (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BASF SE (DE) | 2012-06-28 | — | — | US | disclosed |
| US-7390904-B2 | Hydrogen peroxide catalyzed process for the preparation of sterically hindered N-hydrocarbyloxyamines | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-20050014948-A1 | Hydrogen peroxide catalyzed process for the preparation of sterically hindered N-hydrocarbyloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014948-A1 | Hydrogen peroxide catalyzed process for the preparation of sterically hindered N-hydrocarbyloxyamines | HAO2, SOD1, PPOX | FFAR4 2323/4885PTGER2 4170/4885RBP4 3896/4885 |
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BBOX1, NEFM, NQO1 | FFAR4 3712/4885PTGER2 2518/4885RBP4 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.